» Articles » PMID: 26550137

In-vitro Rescue and Recovery Studies of Human Melanoma (BLM) Cell Growth, Adhesion and Migration Functions After Treatment with Progesterone

Overview
Specialty General Medicine
Date 2015 Nov 10
PMID 26550137
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment of human melanoma (BLM) cells for 48 hrs with progesterone resulted in a significant inhibition of cell growth. The mechanism of growth inhibition was due to autophagy and this action of progesterone was not mediated through progesterone receptor. As cells were floating during treatment, adhesion assay was performed, which showed complete loss of adhesion. When cells were allowed to recover after treatment by culturing in growth medium without progesterone, there was recovery in cell growth. Preliminary experiments on adhesion and recovery cell growth prompted us to suppress autophagic lysosomal degradation with 3-methyladenine (3-MA), which resulted in partial rescue of cell growth, adhesion and migration functions. The above experimental design gave rise to two experimental groups viz., progesterone treated and 3-MA rescued. Since, recovery studies also showed improvement in cell growth, progesterone treated and 3-MA rescued groups were allowed to recover on their own for first 48 hrs and then a second 48 hrs. Comparison of in-vitro cell growth, adhesion and migration functions of progesterone treated, 3-MA rescued and recovered human melanoma cells revealed that the recovery of 3-MA rescued cells was better than the recovery of progesterone treated cells in terms of cell growth and adhesion functions. These in-vitro experiments not only provided the scientific basis for epidemiological findings that menstruating females were better protected in melanoma, but also showed the potential of progesterone to act as an anti-cancer agent for melanoma treatment.

Citing Articles

Sex and Gender Disparities in Melanoma.

Bellenghi M, Puglisi R, Pontecorvi G, De Feo A, Care A, Mattia G Cancers (Basel). 2020; 12(7).

PMID: 32645881 PMC: 7408637. DOI: 10.3390/cancers12071819.


Differential biological effects of dehydroepiandrosterone (DHEA) between mouse (B16F10) and human melanoma (BLM) cell lines.

Joshi K, Hassan S, Ramaraj P Dermatoendocrinol. 2018; 9(1):e1389360.

PMID: 29484102 PMC: 5821161. DOI: 10.1080/19381980.2017.1389360.


Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti R, Limonta P Front Endocrinol (Lausanne). 2016; 7:140.

PMID: 27833586 PMC: 5080294. DOI: 10.3389/fendo.2016.00140.

References
1.
Neifeld J, Lippman M . Steroid hormone receptors and melanoma. J Invest Dermatol. 1980; 74(6):379-81. DOI: 10.1111/1523-1747.ep12544454. View

2.
Jagannath C, Lindsey D, Dhandayuthapani S, Xu Y, Hunter Jr R, Eissa N . Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med. 2009; 15(3):267-76. DOI: 10.1038/nm.1928. View

3.
Ramaraj P, Cox J . In vitro effect of progesterone on human melanoma (BLM) cell growth. Int J Clin Exp Med. 2015; 7(11):3941-53. PMC: 4276160. View

4.
Mather J, Sato G . The growth of mouse melanoma cells in hormone-supplemented, serum-free medium. Exp Cell Res. 1979; 120(1):191-200. DOI: 10.1016/0014-4827(79)90549-4. View

5.
Ratheesh A, Ingle A, Gude R . Pentoxifylline modulates cell surface integrin expression and integrin mediated adhesion of B16F10 cells to extracellular matrix components. Cancer Biol Ther. 2007; 6(11):1743-52. DOI: 10.4161/cbt.6.11.4833. View